基于网络药理学与分子对接技术的乳癖散结胶囊治疗浆细胞性乳腺炎的潜在分子机制研究

Abstract
Figure/Table
References (25)
Related Citation (15)

Download: PDF (3226 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the potential mechanism of Rupi Sanjie Capsules in the treatment of plasma cell mastitis (PCM) by network pharmacology and molecular docking technology. Methods Active ingredients of Rupi Sanjie Capsules and corresponding targets were retrieved by traditional Chinese medicine systems pharmacology database and analysis platform, bioinformatics analysis tool for molecular mechanism of traditional Chinese medicine, and universal protein database, and combined with PCM targets collected from the GeneCards website, potential targets of Rupi Sanjie Capsules for PCM were screened. A drug-ingredient-target-disease network picture was constructed and analyzed for key ingredients, the protein-protein interaction network was built and studied for key targets. Furthermore, key targets and enrichment pathways were studied by gene ontology (GO) and Kyoto database of genes and genomes pathway enrichment analysis. The main components and targets were studied by molecular docking. Results Rupi Sanjie Capsules had 36 potential targets for PCM, protein-protein interaction network suggested that interleukin (IL)-6, epidermal growth factor receptor, albumin, IL-1B, B-cell lymphoma-2L1, chemokine（C-C motif） ligand 2, and catalase were the core targets, related to nuclear factor κB, IL-17, Toll-like receptor signaling pathway, T helper cells 17, mitogen-activated protein kinase signaling pathways, etc., which may regulated cytokine activity, antioxidant activity, and protein phosphatase binding, transmembrane receptor protein kinase activity, cytokine receptor binding and other functions to play roles in the treatment of PCM. Molecular docking suggested that Rupi Sanjie Capsules may improve PCM by affecting apoptosis signals and progesterone secretion. Conclusion Rupi Sanjie Capsules has the comprehensive mechanism of multiple components, multiple targets, and multiple pathways, which may be used in the treatment of PCM.

Key words： Plasma cell mastitis Rupi Sanjie Capsules Signal pathway Network pharmacology

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Zhengjie FANG Kun▲ JIANG Suxiao DUAN Lijuan MAO Chunhua ZHANG Ping

Cite this article:

XU Zhengjie FANG Kun▲ JIANG Suxiao DUAN Lijuan MAO Chunhua ZHANG Ping. Research on the potential molecular mechanism of Rupi Sanjie Capsules in the treatment of plasma cell mastitis based on network pharmacology and molecular docking technology[J]. 中国医药导报, 2022, 19(19): 146-150,168.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I19/146

[1] Chen R，Hu B，Zhang Y，et al. Differential diagnosis of plasma cell mastitis and invasive ductal carcinoma using multiparametric MRI [J]. Gland Surg，2020，9（2）：278-290.
[2] Hu J，Huang X. Combining ultrasonography and mammography to improve diagnostic accuracy of plasma cell mastitis [J]. J Xray Sci Technol，2020，28（3）：555-561.
[3] 彭涛，林志琴，韩翔宇，等.浆细胞性乳腺炎的研究进展[J].赣南医学院学报，2020，40（8）：853-858.
[4] 朱林波，李鹏飞，张鹏斌，等.浆细胞性乳腺炎的诊断与治疗研究进展[J].浙江医学，2019，41（5）：496-498.
[5] 郎玲，齐向秀.中药分期辨证结合情志护理对浆细胞性乳腺炎患者临床疗效研究[J].四川中医，2018，36（2）：199-202.
[6] 王军生.“乳管扩张方”结合中医外治法治疗浆细胞性乳腺炎30例临床观察[J].山西中医学院学报，2018，19（1）：49-50.
[7] 刘宇飞，安甜，王春晖，等.中医治疗浆细胞性乳腺炎评述[J].中医学报，2019，34（2）：289-293.
[8] 韩斐，裴晓华，桂裕亮.乳癖散结胶囊治疗乳腺增生病有效性和安全性的Meta分析[J].山东医药，2018，58（38）：69-72.
[9] 黄科大.手术联合乳癖散结胶囊治疗乳腺增生结节的临床疗效分析[J].临床医学工程，2019，26（4）：501-502.
[10] 乳癖散结胶囊临床应用专家共识组.乳癖散结胶囊治疗乳腺增生病临床应用专家共识[J].中华中医药学刊，2020，38（9）：255-258.
[11] 朱丽华.消乳散结胶囊联合乳癖散结胶囊治疗乳腺增生症临床疗效及对患者血脂、性激素水平的影响[J].河北中医，2018，40（4）：501-505.
[12] Piao CL，Luo JL，Jin D，et al. Utilizing network pharmacology to explore the underlying mechanism of Radix Salviae in diabetic retinopathy [J]. Chin Med，2019，14：58.
[13] Luo TT，Lu Y，Yan SK，et al. Network Pharmacology in Research of Chinese Medicine Formula： Methodology，Application and Prospective [J]. Chin J Integr Med，2020， 26（1）：72-80.
[14] 牟艳芳，陈文璐，周冰，等.基于网络药理学与分子对接技术探讨川蛭通络胶囊干预微循环障碍的机制研究[J].中草药，2021，52（24）：7550-7560.
[15] 刘晓菲，张丽美.中医药对浆细胞性乳腺炎的治疗优势[J].江西中医药，2019，50（11）：72-74.
[16] 聂铮.疏肝益气散结方辅助西医治疗浆细胞性乳腺炎疗效及对免疫球蛋白水平的影响[J].现代中西医结合杂志，2019，28（11）：1201-1203.
[17] 尤广宁，曹中伟.浆细胞性乳腺炎的免疫学研究进展[J].中国疗养医学，2019，28（4）：383-386.
[18] 林小颜，罗建国，胡珊，等.加味阳和汤联合三苯氧胺对浆细胞性乳腺炎患者炎性因子及免疫功能的影响[J].现代中西医结合杂志，2018，27（17）：1840-1842.
[19] 付嘉，熊斌，司传平，等.浆细胞性乳腺炎患者外周血CD4+CD25+CD127-调节性T细胞变化[J].中国免疫学杂志，2013，29（8）：821-824.
[20] 张少波，郑晓宏，钟铁刚.浆细胞性乳腺炎患者外周血Th17细胞的变化[J].临床军医杂志，2015，43（1）：14-16.
[21] 孙厚启.IL-2、IL-4在浆细胞性乳腺炎组织中的表达及意义[D].石河子：石河子大学，2015.
[22] Liu Y，Zhang J，Zhou YH，et al. Activation of the IL-6/JAK2/STAT3 pathway induces plasma cell mastitis in mice [J].Cytokine，2018，110：150-158.
[23] 李毅力，高寒，李达学，等.醋酸泼尼松对浆细胞性乳腺炎患者血清中Treg/Th17比值及炎症因子的影响[J].检验医学与临床，2021，18（7）：945-947，951.
[24] 王华，倪青，高宇哲，等.核因子-κBp65和细胞间黏附分子-1在浆细胞性乳腺炎中的表达意义[J].中华实验外科杂志，2016，33（4）：947-949.
[25] 曹中伟，王潇，尤广宁，等.浆细胞性乳腺炎分期与相关炎性因子及其信号通路的机制研究[J].中西医结合心血管病电子杂志，2019，7（12）：84-85.